Latest 3 stories · newest Oct 28, 2026
TransCode Therapeutics, Inc. announced the initiation of a formal strategic process led by Tungsten Advisors to explore potential transactions for its oncology portfolio, including its lead candidate TTX-MC138. The actions suggest the company is seeking to maximize value with no plans to continue fu…
TransCode Therapeutics reported positive Phase 1a clinical data for its anti-miR-10b candidate TTX-MC138 in advanced solid tumors, with a 71.4% stable disease rate and notable durability. The promising early anti-tumor results support continued development of the RNA therapeutic.
TransCode Therapeutics announced positive Phase 1a results for its lead candidate TTX-MC138, showing safety, tolerability, and disease stabilization in metastatic cancer patients across all dose cohorts. The company will advance to Phase 2a development targeting ctDNA-positive colorectal cancer pati…
The same RNAZ feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/RNAZ/newsSTART FREE